Does Rallies show Form 4 insider transactions for EDIT?

Yes. Rallies tracks EDIT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EDIT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EDIT. It does not provide personalized investment advice.

EDIT (Editas Medicine, Inc. Common Stock) Stock Analysis - Insider Trades

Editas Medicine, Inc. Common Stock (EDIT) is a publicly traded Healthcare sector company. As of May 20, 2026, EDIT trades at $2.57 with a market cap of $247.70M and a P/E ratio of -2.19. EDIT moved +6.10% today. Year to date, EDIT is +30.65%; over the trailing twelve months it is +58.54%. Its 52-week range spans $0.91 to $4.54. Analyst consensus is buy with an average price target of $6.60. Rallies surfaces EDIT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EDIT stock inside the company?

Recent EDIT insider activity includes O'Neill Gilmore Neil sold 5.39K, Parison Amy sold 474, Burkly Linda sold 749, Burkly Linda sold 713, and O'Neill Gilmore Neil sold 5.60K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EDIT Key Metrics

Key financial metrics for EDIT
Metric	Value
Price	$2.57
Market Cap	$247.70M
P/E Ratio	-2.19
EPS	$-1.17
Dividend Yield	0.00%
52-Week High	$4.54
52-Week Low	$0.91
Volume	1.21M
Avg Volume	0
Revenue (TTM)	$38.69M
Net Income	$-108.95M
Gross Margin	0.00%

Recent EDIT Insider Trades

O'Neill Gilmore Neil sold 5.39K (~$10.89K) on Mar 3, 2026.
Parison Amy sold 474 (~$957.48) on Mar 3, 2026.
Burkly Linda sold 749 (~$1.51K) on Mar 3, 2026.
Burkly Linda sold 713 (~$1.54K) on Dec 3, 2025.
O'Neill Gilmore Neil sold 5.60K (~$12.06K) on Dec 3, 2025.

Latest EDIT News

Editas Medicine’s EDIT-401 Cuts LDL-C by ≥90% for Six Months in Primates — May 14, 2026
Editas Medicine Posts Q1 Loss of $25M; Preclinical EDIT-401 Shows >90% LDL-C Drop — May 5, 2026
Editas Medicine Unveils EDIT-401 Preclinical Data Showing LDL-C Reduction Potential — Apr 27, 2026
USPTO Affirms Broad’s CRISPR/Cas9 Patents Again, Solidifying Editas’s IP Foundation — Mar 27, 2026
Editas Beats Q4 EPS by 21c, R&D Revenues $24.7M, Cash Runway to 2027 — Mar 10, 2026

EDIT Analyst Consensus

10 analysts cover EDIT: 0 strong buy, 5 buy, 3 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.60.

Common questions about EDIT

Who is trading EDIT stock inside the company?: Recent EDIT insider activity includes O'Neill Gilmore Neil sold 5.39K, Parison Amy sold 474, Burkly Linda sold 749, Burkly Linda sold 713, and O'Neill Gilmore Neil sold 5.60K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EDIT?: Yes. Rallies tracks EDIT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EDIT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EDIT. It does not provide personalized investment advice.